With finerenone being a targeted therapy, data show there may be an additive cardiorenal benefit when it is coadministered with a sodium glucose co-transporter 2 inhibitor, noted Dipti Itchhaporia, MD, FACC, FAHA, FESC, president of the American College of Cardiology.
Whatever your theory of heart failure with preserved ejection fraction, sodium glucose co-transporter 2 (SGLT2) inhibitors seem to be attacking every one, noted Javed Butler, MD, MPH, MBA, University of Mississippi.
This study is one of only a handful to explore barriers to pulmonary rehabilitation in Iran for patients with chronic obstructive pulmonary disease (COPD).
A new study unveiled on day 2 of ESC Congress 2021 showed finerenone, a nonsteroidal mineralocorticoid receptor antagonist, offers benefits to patients with mild to moderate CKD and type 2 diabetes.
Results of a score-matched analysis showed individuals with hepatocellular cancer reported poor mental health as time progressed after diagnosis.
Research shows higher levels of interleukin 6 in patients with chronic coronary syndrome were associated with an increased risk of cardiovascular events in patients with chronic kidney disease.
The use of potentially inappropriate medications (PIMs) by older adults appeared to be linked to a greater risk of frailty, although the researchers said further work is needed.
Findings from 5 studies presented on day 1 of ESC Congress 2021 indicate that there is still much to be learned on the complex interaction among COVID-19 infection, cardiovascular care, and heart failure.
Sodium glucose co-transporter 2 (SGLT2) inhibitor use in patients with heart failure with preserved ejection fraction (HFpEF) has generated great enthusiasm, noted Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.
Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, talks about the anticipation for more biosimilars to enter the oncology market and the current level of interest in the pipeline.
Patients with multiple sclerosis (MS) who have recovered from COVID-19 and received the B-cell depleting therapy ocrelizumab for at least 1 year were observed to still have T-cell responses.
Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, discusses how greater visual needs are contributing to adverse eye health in younger populations.
EMPEROR-Preserved represents the first trial to show unequivocal benefits of any drug on major heart failure outcomes in patients with heart failure and preserved ejection fraction, the lead investigator said.
The composite end point of cardiovascular death and heart failure hospitalization was reduced by 21%, which is highly statistically significant and clinically meaningful, noted Stefan Anker, MD, PhD, FESC, principal investigator of EMPEROR-Preserved.
A roundup of the latest news in sleep research reported across MJH Life Sciences™.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
FDA halts sale of more than 50,000 flavored e-cigarette products; health systems in Idaho and Oregon struggle to meet the influx of patients with COVID-19; drop in breast cancer screening rates seen throughout pandemic.
The 5-year update could help solidify the role of sodium glucose co-transporter 2 (SGLT2) inhibitors in treating heart failure, years after the first evidence of their effectiveness emerged.
A recent study found that older age, male gender, lack of surgical resection or chemotherapy, and late-stage disease may be poor prognostic factors for diffuse large B-cell lymphoma (DLBCL) of the urinary tract.
Although there is an established link between type 2 myocardial infarction (T2MI) and elevated rates of cardiovascular events, less is known about the connection between T2MI and heart failure—which this new study investigated.
Researchers said the blood test offers an earlier warning of hepatocellular carcinoma than current methods.
Foundation Medicine and Epic struck a deal to integrate comprehensive genomic profiling within Epic's electronic health records (EHRs), allowing for providers to order and review genomic profiling tests, leading to more streamlined clinical decision making.
Researchers offer recommendations for addressing polypharmacy and potentially inappropriate medication (PIM) use among older patients with cancer.
Patients with psoriasis who received biologic treatments were at significantly lower risk of developing psoriatic arthritis, with women representing a potentially at-risk group.
The United States Preventive Services Task Force (USPSTF) lowered its recommended screening age for type 2 diabetes and prediabetes from 40 to 35 years among overweight and obese individuals.
Delta Air Lines raises health insurance premiums for employees not vaccinated against COVID-19; the Pentagon requires all active-duty service members to receive a COVID-19 vaccine; 2 mental health giants merge into 1 company worth $3 billion.
An overview of the latest news in Parkinson disease reported across clinical research.
The genomic alterations in prostate cancer were detected from tissue biopsies of primary tumors and metastatic sites as well as from liquid biopsies of circulating tumor DNA, the latter of which has emerged as an increasingly popular method for genomic analyses across various types of cancer.
There are incredible data for sodium-glucose co-transporter 2 (SGLT2) inhibitors, and this is a great class of medicines that is vastly underutilized, stated Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School.
Approximately 1 in 6 healthy individuals who underwent proactive genetic screening had genetic variants linked to increased risk for developing medically actionable disorders, including certain cancers and cardiovascular disorders.
